Authors: Andric, V.; Nevers, A.; Hazra, D.; Auxilien, S.; Menant, A.; Graille, M.; Palancade, B.; Rougemaille, M.
De novo drug designing coupled with brute force screening and structure guided lead optimization gives highly specific inhibitor of METTL3: a potential cure for Acute Myeloid Leukaemia